Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aubagio

- PMLiVE

Dupixent gains can’t keep Sanofi on a growth track

Reports fall in Q3 sales despite growth of immunology drug

- PMLiVE

Sanofi/Regeneron wins another EU approval for Dupixent

Becomes first biologic approved in EU for CRSwNP indication

- PMLiVE

J&J expands Darzalex use with another first-line FDA approval

Could help defend myeloma franchise against rival Sanofi

EU flag

GW Pharma’s Epidyolex gets EU approval for severe epilepsy

Company is confident it can overturn preliminary 'no' from NICE

- PMLiVE

New data backs GeNeuro’s MS drug after Servier exit

Search continues for new development partner

- PMLiVE

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Sets up regulatory filings and possible approval next year

Sanofi reception

Sanofi exits Zynquista alliance with Lexicon

Will pay $260m to end collaboration

- PMLiVE

Merck takes evobrutinib for MS into phase 3, on mixed data

First drug in class to reach this stage for the illness

- PMLiVE

Novo follows Sanofi, Lilly with insulin price cut in US

Price cut will be effective from January 2020

- PMLiVE

NHS leaders warn of no-deal Brexit flu vaccine delays

Follows prior delay in production of the vaccine

- PMLiVE

Sanofi patent case win holds off generic rivals for key cancer drug

Boosts hope of increasing future sales

- PMLiVE

The fight for affordable insulin

Activists are organised, and demanding action on US insulin prices - and pointing the finger at pharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links